Application of OC-STAMP (osteoclast stimulatory transmembrane protein) as prognostic risk marker in evaluating multiple myeloma patients

A multiple myeloma, patient technology, applied in the field of medical detection, can solve problems such as lack of specific molecular biological markers

Active Publication Date: 2020-01-31
北京金域医学检验实验室有限公司
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In terms of prognostic stratification and curative effect evaluation, cytogenetic and biochemical indicators are often relied on, and specific molecular biological markers are lacking.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of OC-STAMP (osteoclast stimulatory transmembrane protein) as prognostic risk marker in evaluating multiple myeloma patients
  • Application of OC-STAMP (osteoclast stimulatory transmembrane protein) as prognostic risk marker in evaluating multiple myeloma patients
  • Application of OC-STAMP (osteoclast stimulatory transmembrane protein) as prognostic risk marker in evaluating multiple myeloma patients

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1. Application of OC-STAMP as a risk marker for assessing the prognosis of patients with multiple myeloma

[0043] 1. Research objects and methods

[0044] 1. Research object

[0045] From January 2014 to December 2016, the bone marrow samples of 160 newly diagnosed multiple myeloma patients (all patients gave informed consent) admitted to the Institute of Blood Diseases of Peking University People's Hospital were collected as research objects, including 100 male cases, There were 60 females, with a median age of 60 years and an age range of 33 to 87 years. They were followed up until death, loss of follow-up or August 2019. The diagnostic criteria of multiple myeloma refer to the guidelines of the National Comprehensive Cancer Network (NCCN), and the staging is carried out according to the Durie-Salmon (D-S) staging system, the International Staging System (ISS) and the Revised International Staging System (R-ISS). The treatment and curative effect evaluation...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of application of OC-STAMP (osteoclast stimulatory transmembrane protein) as a prognostic risk marker in evaluating multiple myeloma patients. According to the application, expression levels of OC-STAMP in bone marrow cells of newly diagnosed and released MM (multiple myeloma) patients and healthy donors are analyzed by using an RT-qPCR (real-time-quantitative real time polymerase chain reaction) method, and results show that the expression level of the gene in an MM patient is remarkably higher than that of a normal reference level and is possibly related to clinical courses. Subsequently, the clinical significance of the gene is investigated and results show that high expression of the gene is an independent risk factor of low progression-free survival(PFS) of the MM patient. OC-STAMP has important value in evaluating the prognostic risk of the multiple myeloma patients.

Description

technical field [0001] The invention belongs to the technical field of medical detection, and in particular relates to the application of OC-STAMP as a prognostic risk marker for evaluating multiple myeloma patients. Background technique [0002] Multiple myeloma (Multiple Myeloma, MM) is the second most common hematological malignancy originating from plasma cells, accounting for 10-15% of all hematological tumors. Myeloma cells proliferate malignantly in the bone marrow and secrete monoclonal immunoglobulins, which can lead to organ and tissue damage. Bone marrow infiltration leads to suppression of normal hematopoiesis leading to anemia, infection, and bleeding. Infiltration in the bone stimulates osteoclasts to enhance their osteolysis, leading to bone pain, bone defects, hypercalcemia, and pathological fractures. Primary disease is prone to occur in the elderly, the average age of onset is about 70 years old, and the ratio of male to female is (1.6-3):1. At present, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G01N33/68G01N33/574
CPCC12Q1/6886G01N33/68G01N33/57407G01N33/57492C12Q2600/158C12Q2600/118G01N2333/705
Inventor 黄晓军阮国瑞路瑾王子龙周亚兰吴利新
Owner 北京金域医学检验实验室有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap